We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.


7 June 2012 By Robert Cyran

The name for the $165 bln pharma giant’s veterinary business – Zoetis – is pretty awful, but its prospects are bright. The coming IPO and separation of the unit, maybe worth $16 bln, underline Pfizer’s more than 15 percent valuation discount to peers. The gap isn’t justified.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)